2018 Convention Social Worker Evaluation Summary Question Title * 1. Contact Information Name Credentials Email Address Phone Number Question Title * 2. Overall impression of Convention 5 4 3 2 1 Question Title * 3. Registration, Check-in and Assistance 5 4 3 2 1 Question Title * 4. Meeting Rooms 5 4 3 2 1 Question Title * 5. Exhibits 5 4 3 2 1 Question Title * 6. Meals 5 4 3 2 1 Question Title * 7. Hotel Accommodations 5 4 3 2 1 Question Title * 8. Objective #1: Demonstrate in an effective manner procedures for addressing pain crisis in various settings. 5 4 3 2 1 Question Title * 9. Objective #2: Utilize evidence-based guidelines and best practices in their daily care of self and patients to improve patient outcomes and quality of life. 5 4 3 2 1 Question Title * 10. Objective #3: Identify alternate treatment options for the care of themselves and patients. 5 4 3 2 1 Question Title * 11. Objective #4: Use clinical trials websites to access information regarding participation in various available clinical trials. 5 4 3 2 1 Question Title * 12. Objective #5: Decrease the amount of fragmentation in care from adolescent to adult providers. 5 4 3 2 1 Question Title * 13. Objective #6: Recognize, identify or assist in the development of social and emotional resources for patients and families. 5 4 3 2 1 Question Title * 14. Relationship of objectives to overall purpose/goals of activitiy 5 4 3 2 1 Question Title * 15. Wednesday Registration 5 4 3 2 1 Question Title * 16. HRSA Grant Team Meeting 5 4 3 2 1 Question Title * 17. SCDAA Member Training 5 4 3 2 1 Question Title * 18. Thursday Registration 5 4 3 2 1 Question Title * 19. Thursday Breakfast 5 4 3 2 1 Question Title * 20. Thursday Speed Networking 5 4 3 2 1 Question Title * 21. SCDAA BUSINESS SESSION 5 4 3 2 1 Question Title * 22. Opening Ceremony 5 4 3 2 1 Question Title * 23. Treatment Demonstration Grant Updates: Rosemary Britt 5 4 3 2 1 Question Title * 24. Newborn Screening Grant Update: Kathy Norcott 5 4 3 2 1 Question Title * 25. PICORI Grant Update: Mary Lamar 5 4 3 2 1 Question Title * 26. Hemolytic Anemia in Sickle Cell Disease: What is it and why Does it Matter? 5 4 3 2 1 Question Title * 27. Sickle Cell Basics: Wanda Whitten- Shurney, MD 5 4 3 2 1 Question Title * 28. Developing My Healthcare Passport: Andre Harris 5 4 3 2 1 Question Title * 29. Hydroxyurea and Transfusions: Andrew Campbell, MD 5 4 3 2 1 Question Title * 30. Effective Transition: Leila Jerome-Clay, MD, MCTS 5 4 3 2 1 Question Title * 31. Chronic Organ Damage: Caterina Minniti, MD 5 4 3 2 1 Question Title * 32. Virtual Reality as an Adjunct Pain Management Therapy: Latika Puri, MD 5 4 3 2 1 Question Title * 33. The Opioid Crisis and Nursing Ramifications: Yvonne Carroll, RN, JD 5 4 3 2 1 Question Title * 34. The Opioid Crisis- Non Opioid Pain Management Treatment Options: Genice T. Nelson, DNP, APRN,ANP-BC 5 4 3 2 1 Question Title * 35. Telementoring: Sophie Lanzkron, MD, MHS 5 4 3 2 1 Question Title * 36. Chronic Pain: Deepika Darbari, MD 5 4 3 2 1 Question Title * 37. Transplantation Update: Courtney Fitzhugh, MD 5 4 3 2 1 Question Title * 38. Managing Sickle Cell Disease in Older Adults: Swee Lay Thein 5 4 3 2 1 Question Title * 39. Using Implementation Science to Develop and Evaluate Psychosocial Interventions in SCD: Lori Crosby, PsyD 5 4 3 2 1 Question Title * 40. Examining Spiritual Well Being During Health Care Transition for Adolescents and Emerging Adults with Sickle Cell Disease: Dora Clayton- Jones, RN, PhD, CPNP-PC 5 4 3 2 1 Question Title * 41. Peer Mentoring vs. Structured Education to Improve Transition to Adult Care in SCD: Ify Osunkwo, MD, MPH 5 4 3 2 1 Question Title * 42. Community Health Worker vs. A Mobile app to Improve Transition to Adult Care: Kim Smith-Whitley, MD, MPH 5 4 3 2 1 Question Title * 43. Community Health Worker Training 5 4 3 2 1 Question Title * 44. PCORI: Lori Crosby, PsyD 5 4 3 2 1 Question Title * 45. Clinical Trail Update 5 4 3 2 1 Question Title * 46. Dr. Biree Andemariam 5 4 3 2 1 Question Title * 47. GBT 5 4 3 2 1 Question Title * 48. Emmaus 5 4 3 2 1 Question Title * 49. Prolong Pharmaceuticals 5 4 3 2 1 Question Title * 50. Imara 5 4 3 2 1 Question Title * 51. Pfizer 5 4 3 2 1 Question Title * 52. Novartis 5 4 3 2 1 Question Title * 53. Bluebird bio 5 4 3 2 1 Question Title * 54. Bioverative 5 4 3 2 1 Question Title * 55. Ironwood Pharmaceuticals 5 4 3 2 1 Question Title * 56. Poster Session 5 4 3 2 1 Question Title * 57. Chairman's Reception and Generation S "Rock the Block" Eve Pisces 5 4 3 2 1 Question Title * 58. Friday Registration 5 4 3 2 1 Question Title * 59. Friday Breakfast 5 4 3 2 1 Question Title * 60. Friday Speed Networking 5 4 3 2 1 Question Title * 61. Real Life Experience with Transplantation: Patient and Family perspective: Wanda Whitten Shurney, MD 5 4 3 2 1 Question Title * 62. Charles F. Whitten, MD Memorial Lecture Dr. Wanda Whitten-ShurneyWe've Fallen But We Must Get Up: Dizziness, Falling and Hearing Loss in Individuals Living With Sickle Cell Disease. M. Dawn Nelson, Ph.D. CC-A 5 4 3 2 1 Question Title * 63. Diversity Panel 5 4 3 2 1 Question Title * 64. Community Health Worker Training 5 4 3 2 1 Question Title * 65. Healing The Healer Provider Session: Wanda Whitten-Shurney, MD 5 4 3 2 1 Question Title * 66. Self-Advocacy 101 for Individuals with SCD: Carla Lewis 5 4 3 2 1 Question Title * 67. Finding your Voice between the Patient and Caregiver: Trudy Tchume- Johnson, LSW, Velvet Brown Watts, MSW, CM 5 4 3 2 1 Question Title * 68. Lonzie Lee Jones Patient Advocacy Symposium: SCD Hollywood Squares - Celebrating Patient Family Victories 5 4 3 2 1 Question Title * 69. Patient and Caregiver Perspectives on Areas of Burden in Sickle Cell Disease Management: Tilicia Mayo-Gamble, PhD, MPH, MA, CHES 5 4 3 2 1 Question Title * 70. Finding SCD Patients in Michigan- A Case Study: Wanda Whitten-Shurney, MD, Jeanne M. Loboda 5 4 3 2 1 Question Title * 71. The Communication, Awareness, Relationship and Empowerment Model: An Effective Tool for Engaging Urban Communities in Community-Based Participatory Research: Marlene Peters- Lawerence, BSN, RN, RRT 5 4 3 2 1 Question Title * 72. Technology Access and Preferences for Smartphone Application Content Among Adults with Sickle Cell Disease and their Caregivers: Tilicia Mayo-Gamble, PhD, MPH, MA, CHES 5 4 3 2 1 Question Title * 73. Digital Engagement in the Sickle Cell Community: Robin C. Howard 5 4 3 2 1 Question Title * 74. Novel Ways to Recruit New Health Care Professionals into the Sickle Cell Arena: Donna Pennington Monroe, MS 5 4 3 2 1 Question Title * 75. Geography Seems to be A Factor that Determines the Outcome of Transition for Children with Sickle Cell Disease into Adult Programs: Nina Anderson, RN, DNP 5 4 3 2 1 Question Title * 76. Loneliness Predicts Next-Day Quality of Life in Sickle Cell Disease: A Micro-Longitudinal Analysis: Shawn Bediako, PhD 5 4 3 2 1 Question Title * 77. Discovering and Breaking Down Barriers: Improving Compliance with Appointments in the Pediatric Sickle Cell Clinic: Carla Jones, MSN, RN, Kenneth Mitten, MSW 5 4 3 2 1 Question Title * 78. The Need For Free Sickle Cell Trait Screening Services in America: Gary Gibson 5 4 3 2 1 Question Title * 79. The Opioid Epidemic and CDC Guidelines: A Case of an Unfortunate Consequences Paved by Good Intentions: Cynthia Sinha, PhD 5 4 3 2 1 Question Title * 80. Availability of Information on Blood Marrow Transplantation (BMT) Coverage Benefits for Patients with Sickle Cell Disease (SCD) Enrolled in Medicaid: Tatenda Mupfudze, PhD 5 4 3 2 1 Question Title * 81. Stigma Moderates the Association Between SCD Pain Frequency and Emergency Department Utilization: Shawn Bediako, PhD 5 4 3 2 1 Question Title * 82. A Training Approach for Newborn Screening Personnel in Nigeria: Lewis Hsu, MD 5 4 3 2 1 Question Title * 83. The Importance of Social Work in Complex SCD Care: A Model for Clinical Intervention: Teresa Works, MSW, LCSW 5 4 3 2 1 Question Title * 84. The Forgotten Vital Sign: Use of A Distress Thermometer With Children, Adolescents and Young Adults Diagnosed with Sickle Cell Disease: Kenneth Mitten, MSW 5 4 3 2 1 Question Title * 85. Effect of Long Term Treatment With Sc411 on Sickle Cell Crisis Rate In Children With Sickle Cell Disease: Beng Fuh, MD 5 4 3 2 1 Question Title * 86. Compassionate-Use Voxelotor (GBT440) For up to 2 Years in Patients with Severe Sickle Cell Disease and Life-Threatening Comorbidities: Kenneth R. Bridges, MD 5 4 3 2 1 Question Title * 87. Crizanlizumab 5.0Mg/Kg Increased the Time to First On-Treatment Sickle Cell Pain Crisis (SCPC) and the likelihood of not expecting experiencing SCPC While On Treatment: Subgroup Analyses of the Phase 2 Sustain Study: Julie Kanter, MD 5 4 3 2 1 Question Title * 88. Parent and Youth Barriers to Hydroxyurea Adherence in Adolescents with Sickle Cell Disease: Arlene Smaldone, PhD, CPNP, CDE 5 4 3 2 1 Question Title * 89. Sickle Cell Patients With Leg Ulcers Have a Pro-Thrombotic Profile: Ugochi Ogu, MD 5 4 3 2 1 Question Title * 90. Crizanlizaumab Treatment is not Associated With the Development of Proteinuria and Hematuria in Patients with Sickle Cell Disease: Sustain Study Safety Analysis: Julie Kanter, MD 5 4 3 2 1 Question Title * 91. Genome Editing to Fix the Sickle Cell Disease Causing Variant in Sickle Cell Patient Hematopoietic Stem Cells: Matthew Porteus, MD, PhD 5 4 3 2 1 Question Title * 92. Correction of the Sickle Mutation in Hematopoietic Stem/Progenitor Cells with CRISPR/Cas9: The Berkeley/UCSF/UCLA Sickle Cell Clinical Transplantation Project: Mark Dewitt 5 4 3 2 1 Question Title * 93. The Clinical-Stage SGC Stimulator Olinciguat Prevents Increase Of Plasma Biomarkers Of Intravascular Inflammation And Suppresses Leukocyte-Endothelial Interactions In Tnfa-Treated Mice: Boris Tchernychev 5 4 3 2 1 Question Title * 94. Strategies and Next Steps for Improving Sickle Cell Disease Care: Highlights from The Sickle Cell Disease Treatment Demonstration Program 5 4 3 2 1 Question Title * 95. Striving in the Workforce with Sickle Cell: Terri Booker, Esq. & Carla Lewis 5 4 3 2 1 Question Title * 96. Red Carpet Reception Featuring Red Carpet Interviews 5 4 3 2 1 Question Title * 97. UNITY SOIREE 5 4 3 2 1 Next